<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EAAD4D43-BD15-432B-9385-2DBD0C65958D"><gtr:id>EAAD4D43-BD15-432B-9385-2DBD0C65958D</gtr:id><gtr:name>University of Bath</gtr:name><gtr:department>Pharmacy and Pharmacology</gtr:department><gtr:address><gtr:line1>University of Bath</gtr:line1><gtr:line2>Claverton Down</gtr:line2><gtr:line4>Bath</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BA2 7AY</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EAAD4D43-BD15-432B-9385-2DBD0C65958D"><gtr:id>EAAD4D43-BD15-432B-9385-2DBD0C65958D</gtr:id><gtr:name>University of Bath</gtr:name><gtr:address><gtr:line1>University of Bath</gtr:line1><gtr:line2>Claverton Down</gtr:line2><gtr:line4>Bath</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BA2 7AY</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/BBFC56B8-EBBC-431F-BA98-1E4743EE74C7"><gtr:id>BBFC56B8-EBBC-431F-BA98-1E4743EE74C7</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:surname>Ward</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DDEA3AE9-64F8-4EC0-BFBC-58EF44134019"><gtr:id>DDEA3AE9-64F8-4EC0-BFBC-58EF44134019</gtr:id><gtr:firstName>James</gtr:firstName><gtr:surname>Dowden</gtr:surname><gtr:orcidId>0000-0002-7825-8971</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0700840"><gtr:id>B6C31E12-3A1C-4789-9C1F-D701040C4FB2</gtr:id><gtr:title>The role of protein arginine methylation in T lymphocyte migration</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700840</gtr:grantReference><gtr:abstractText>We are interested in working out the fundamental mechanisms that orchestrate the way that white blood cells recognise and migrate toward sites of tissue inflammation. This will help in the design of not only new effective anti-inflammatory drugs but also anti-cancer drugs, since the spread of various tumour cells also relies on similar migratory mechanisms.

A family of molecules referred to as chemokines act as ?homing beacons? and direct cells to the site of tissue injury where they are required to fight infection or respond to tissue injury. 

When the resolution of inflammation is impaired and/or the inflammatory response is switched on inappropriately, cells accumulate in tissues unnecessarily, leading to a range of inflammatory or autoimmune diseases. 

Biochemical signals within cells convey information that allow cells to move in response to chemokines and provide a sense directionality. Professor Ward has uncovered new evidence that addition of so-called methyl groups to proteins could be an important mechanism for cell migration. 

We plan to use a combined molecular and chemical approaches that provide the most powerful way to control and learn about individual methylated proteins within cells and organisms. Ultimately, the chemicals and information that we obtain may be combined for future development of new drugs that may block unwanted cell migration.</gtr:abstractText><gtr:technicalSummary>This proposal describes a ?proof-of concept? pilot strategy to probe the functional importance of protein methyl arginine transferases and assess whether this post-translational event is receptor regulated. We envisage that chemical interference represents the most appropriate means of characterising the dynamic role of this protein class (for example in T lymphocyte migration) and therefore seek to evaluate rationally designed chemical inhibitors. We recognise that there may be opportunities for new therapeutic interventions in a range of diseases. At the end of this study, we will be well placed to embark on a programme of research to set out to characterise the role of the PRMTs and fully exploit targeting of this pathway. We therefore aim to:
(i) Explore the hypothesis that arginine methylation is a receptor regulated event in the response of T lymphocytes to chemokines. 
(ii) Address the significant paucity of potent small molecule pharmacological tools directed against protein arginine methyltransferases and amenable to rational improvement.</gtr:technicalSummary><gtr:fund><gtr:end>2010-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>383489</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Chemistry Nottingham</gtr:department><gtr:description>Development of novel PRMT inhibitors</gtr:description><gtr:id>2BA3A48A-53ED-4B3E-8408-E2D58FAC2333</gtr:id><gtr:impact>2 publicaitons</gtr:impact><gtr:outcomeId>fbWrfmkSYxX-1</gtr:outcomeId><gtr:partnerContribution>Nottingham have provided chemical tools to researchers in Bath who have characterized these compounds in terms of inhibition of PRMT isoforms and biological function. Results are fed back to Nottingham for structure vs activity relationship comparisons which allows further refinement to chemical structure so as to optimise activity and specificity of action.</gtr:partnerContribution><gtr:piContribution>Pharmacological analysis of novel compounds</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Royal Society Labs to Riches</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>86C37721-C467-43AB-B8B1-423C84A79398</gtr:id><gtr:impact>Poster

None to report</gtr:impact><gtr:outcomeId>3378603AD10</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Keynote lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5701D453-6674-40B4-A3A0-1C32E2B1EA04</gtr:id><gtr:impact>lecture

None to date</gtr:impact><gtr:outcomeId>4DC076B408B</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>Inhibitors show selectivity against arginine methyltransferases vs lysine methyltransferases.</gtr:description><gtr:id>0F85C272-A5F6-47B1-817A-7D84C11D1228</gtr:id><gtr:impact>None to date- awaiting submission/publication of first paper.</gtr:impact><gtr:outcomeId>38A30A0F3D5</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Protein arginine methyltransferase inhibitor</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>These compounds will help identify functional significance of arginine methylation</gtr:description><gtr:id>8D63C1F6-75CF-4C69-A36B-11BE79E7AEC3</gtr:id><gtr:impact>These compounds will help identify functional significance of arginine methylation and may leasd to novel anti-inflammatory and anti-cancer drugs</gtr:impact><gtr:outcomeId>9E1C04C55A9</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Protein arginine methyltransferase inhibitors</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>95E82EA1-0716-4745-8244-952D1FEAA85D</gtr:id><gtr:title>Protein arginine methylation: a new handle on T lymphocytes?</gtr:title><gtr:parentPublicationTitle>Trends in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5c22df921993100e44bf8b7bcc4f965"><gtr:id>b5c22df921993100e44bf8b7bcc4f965</gtr:id><gtr:otherNames>Parry RV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1471-4906</gtr:issn><gtr:outcomeId>aDhHDgBys48</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2BF23427-EE58-4C83-9E7C-2FD38C030A54</gtr:id><gtr:title>Small molecule inhibitors that discriminate between protein arginine N-methyltransferases PRMT1 and CARM1.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d54867df83bb1d003110c7f9a8acc4d4"><gtr:id>d54867df83bb1d003110c7f9a8acc4d4</gtr:id><gtr:otherNames>Dowden J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn><gtr:outcomeId>omeUA21JbeD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0BB61EB5-D298-48C6-9D20-202D10EB46B1</gtr:id><gtr:title>Facile synthesis of N-6 adenosine modified analogue toward S-adenosyl methionine derived probe for protein arginine methyltransferases</gtr:title><gtr:parentPublicationTitle>Chinese Chemical Letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/449c17b3f742e55e1a6b83af64dc94b4"><gtr:id>449c17b3f742e55e1a6b83af64dc94b4</gtr:id><gtr:otherNames>Hong W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>doi_55f984984706a8b8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BCEC23C2-8F86-4B77-98D0-E8DFD92E5B81</gtr:id><gtr:title>Toward the development of potent and selective bisubstrate inhibitors of protein arginine methyltransferases.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d54867df83bb1d003110c7f9a8acc4d4"><gtr:id>d54867df83bb1d003110c7f9a8acc4d4</gtr:id><gtr:otherNames>Dowden J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>iHBYh1X8SY9</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700840</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>